Is 000590.SZ overvalued or undervalued?

000590.SZ currently has a P/E ratio of -45.27. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Guhan Pharmaceutical Group Co., Ltd. stock?

Guhan Pharmaceutical Group Co., Ltd. trades on SHZ. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 000590.SZ?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 000590.SZ protect my money against local inflation?

Many investors in Latin America buy international stocks like 000590.SZ to protect their purchasing power. Because 000590.SZ is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 000590.SZ shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 000590.SZ a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 000590.SZ diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks000590.SZ

Guhan Pharmaceutical Group Co., Ltd.

¥9.18+¥0.13+1.44%

SHZ / CNY

Market cap

¥2.2B

P/E

-45.3

EPS (TTM)

¥-0.03

Dividend yield

—

Beta

0.22

1Y return

-21.47%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$47M2021

$51M2022

$57M2023

$47M2024

$48M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.24Low
Current ratio1.92
Cash ratio0.57
Net margin-14.7%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

000590.SZ-45.3
Healthcare sector median26.8
S&P 50022.0

Trades about 269% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.74
Price to book4.13
EPS (TTM)¥-0.03
Payout ratio-268%
FCF yield-0.74%

Range & risk

¥7.47¥12.90

Trading in the lower third of its 52-week band

Beta0.22

Profile

What Guhan Pharmaceutical Group Co., Ltd. actually does

Guhan Pharmaceutical Group Co., Ltd., along with its various subsidiaries, operates as a prominent Chinese pharmaceutical enterprise. The company focuses on the production and distribution of traditional Chinese medicine (TCM), conventional chemical pharmaceuticals, and health supplements within the domestic market. Its business activities are organized into specific segments, including the manufacturing and sale of traditional Chinese medicine, the manufacturing and sale of Western medicine, and a range of other operations. The company boasts a comprehensive product catalog featuring both prescription and over-the-counter (OTC) drugs. This selection includes tonics and health-boosting preparations, medications for cardiovascular and cerebrovascular conditions, nutritional products for children, cold and flu remedies, and detoxifying agents. Beyond its core manufacturing, Guhan Pharmaceutical is involved in a diverse array of additional services and ventures. These encompass health and nutrition advisory services, the cultivation of Chinese medicinal herbs, extensive medical research and experimental development, planning for cultural and artistic exchanges, general medical consultations, online sales, technology promotion, consulting agent services, outpatient care, and comprehensive pharmaceutical wholesale and retail operations. Founded in 1956, the company is headquartered in Hengyang, China. It was previously known as Tus-Pharmaceutical Group Co., Ltd., officially adopting its current name, Guhan Pharmaceutical Group Co., Ltd., in November 2025.

CEO

Xue Feng

Employees

1,064

Headquarters

Hengyang, HU

Founded

1996-01-19

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 000590.SZ and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

000590.SZ has a beta of 0.22, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Guhan Pharmaceutical Group Co., Ltd.